North America Autoinjectors Market Size and Forecast (2021

Description

List of Tables

The North America Autoinjectors Market is projected to reach US$ 4,788.3 Million by 2034, rising from US$ 1,578.6 Million in 2025. The market is anticipated to expand at a CAGR of 13.4% during the forecast period from 2026 to 2034.

Executive Summary and North America Autoinjectors Market Analysis:

The North America autoinjectors market is witnessing substantial growth, supported by the increasing prevalence of chronic illnesses, allergic conditions, and other disorders requiring injectable medications that can be administered by patients themselves. According to the International Diabetes Federation's 2025 estimates, approximately 10.8% of adults aged 20-79 across North America and the Caribbean were living with diabetes, creating significant demand for convenient injectable drug-delivery solutions and self-administration devices.

The region also faces a considerable burden of allergic diseases. In the US, approximately 31.7% of adults in 2024 had been diagnosed with seasonal allergy, eczema, or food allergy. Severe allergic reactions can progress to anaphylaxis, where rapid administration of epinephrine through an autoinjector can be critical. The combination of chronic disease prevalence and widespread allergies is therefore generating demand for multiple categories of autoinjectors, ranging from emergency epinephrine devices to sophisticated systems used for biologic therapies and autoimmune conditions.

Technological progress is further strengthening market development. Manufacturers are introducing smart and connected autoinjectors with improved ergonomic designs, safety mechanisms, and usability features that can support treatment adherence and simplify administration at home. The region's well-developed healthcare infrastructure, favorable reimbursement environment, increasing acceptance of self-care, and strong patient preference for convenient treatment options are contributing to wider adoption. As injectable therapies increasingly move into home-based care, autoinjectors are becoming an important component of both chronic disease management and emergency treatment.

Strategic Insights

North America Autoinjectors Market Segmentation Analysis:

By Type, the North America Autoinjectors Market is segmented into Disposable Prefilled Syringes and Reusable Prefilled Syringes. The Disposable Prefilled Syringes segment held the largest market share in 2025.
By Applications, the North America Autoinjectors Market is categorized into Cancer, Diabetes, Autoimmune Disease, Infectious Diseases, and Others. The Others segment accounted for the dominant share in 2025.
By Distribution Channel, the North America Autoinjectors Market is divided into Hospital Pharmacy, Retail Pharmacy, and Online Channel. The Hospital Pharmacy segment dominated the market in 2025.

Market Report Scope

North America Autoinjectors Market Outlook

Chronic conditions such as diabetes, rheumatoid arthritis, multiple sclerosis, and various autoimmune disorders frequently require patients to receive injections on a recurring basis. According to the International Diabetes Federation's 2025 Diabetes Atlas, approximately 11.1% of adults aged 20-79 worldwide, representing nearly 589 million people, were living with diabetes in 2024. This growing disease burden is increasing the number of individuals who require insulin and other injectable therapies, thereby supporting demand for convenient self-administration technologies.

The World Health Organization has also reported a substantial long-term increase in the global diabetic population, from approximately 200 million people in 1990 to more than 828 million by 2024. This trend highlights the expanding need for practical drug-delivery technologies that can be used outside conventional clinical settings.

A growing number of patients manage chronic diseases at home, making ease of use an important consideration when selecting injection devices. Autoinjectors can simplify administration by reducing the number of manual steps involved in delivering medication and potentially improving treatment adherence. Their convenience can also reduce the need for frequent visits to healthcare facilities for routine injections.

As healthcare systems increasingly emphasize home-based treatment, patient independence, and self-management, demand for reliable and user-friendly injection devices is expected to continue increasing. The combination of rising disease prevalence, growing use of injectable medicines, and the shift toward decentralized care is therefore expected to remain a key factor supporting the North America autoinjectors market.

North America Autoinjectors Market Country Insights

By country, the North America Autoinjectors Market is segmented into the United States, Canada, and Mexico. The United States accounted for the largest market share in 2025.

The US represents the region's leading autoinjector market, supported by the high prevalence of chronic diseases and allergic disorders. Official US data indicate that approximately 31.7% of adults had been diagnosed with seasonal allergy, eczema, or food allergy in 2024. This substantial allergic disease burden creates significant demand for epinephrine autoinjectors for emergency treatment of severe reactions, including anaphylaxis.

Beyond allergy treatment, patients with diabetes, rheumatoid arthritis, and other chronic or autoimmune conditions increasingly rely on biologic and injectable therapies that can be administered outside healthcare facilities. Autoinjectors provide a convenient delivery option for many of these treatments, supporting their growing role in home-based care.

The US market is also benefiting from continued product development. New disposable autoinjector platforms introduced in 2025 have focused on improved usability, patient safety, and ease of administration. Partnerships designed to support the supply of delivery systems for home-based chronic therapies further demonstrate the industry's focus on patient-centered treatment.

Strong healthcare infrastructure, regulatory support, established reimbursement mechanisms, and high awareness of self-administration technologies are facilitating adoption. Increasing public awareness of allergy risks and chronic disease management is also encouraging patients to seek convenient treatment options. Consequently, the US is expected to maintain its position as the primary market for autoinjectors in North America.

North America Autoinjectors Market Company Profiles

Major companies operating in the market include Phillips-Medisize, Gerresheimer AG, West Pharmaceutical Services Inc, Ypsomed Holding AG, Stevanato Group SpA, Becton Dickinson and Co, Owen Mumford Ltd, Haselmeier GmbH, Nemera, and SHL Medical.

These companies are pursuing strategies such as geographic expansion, product innovation, strategic partnerships, manufacturing expansion, and mergers and acquisitions. Such initiatives are designed to introduce advanced drug-delivery technologies, improve device usability and safety, respond to evolving pharmaceutical requirements, strengthen production capabilities, and increase market share in the North American autoinjectors industry.

Product Code: TIPRE00043952

1. Executive Summary

1.1 Analyst Market Outlook

2. Global Autoinjectors Market Landscape

2.1 Overview
2.2 Value Chain Analysis
2.3 Supply Chain Analysis
- 2.3.1 List of Manufacturers/Suppliers
- 2.3.2 List of Potential Customers (Upto 50)
2.4 Porter's Five Forces Analysis
2.5 PEST Analysis

3. Competitive Landscape

3.1 Company Benchmarking by Key Players
3.2 Market Share Analysis, 2025 - By Key Players
3.3 Market Concentration

4. North America Autoinjectors Market - Key Industry Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Future Trends
4.5 Impact of Drivers and Restraints:

5. Autoinjectors Market - North America Analysis

5.1 North America Autoinjectors Market Revenue (US$ Million), 2021 - 2034
5.2 North America Autoinjectors Market Revenue Forecast and Analysis

6. North America Autoinjectors Market Revenue Analysis - by Type

6.1 North America Autoinjectors Market Forecast and Analysis by Type
- 6.1.1 Disposable Prefilled Syringes
  - 6.1.1.1 Overview
  - 6.1.1.2 Disposable Prefilled Syringes: North America Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 6.1.2 Reusable Prefilled Syringes
  - 6.1.2.1 Overview
  - 6.1.2.2 Reusable Prefilled Syringes: North America Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

7. North America Autoinjectors Market Revenue Analysis - by Applications

7.1 North America Autoinjectors Market Forecast and Analysis by Applications
- 7.1.1 Cancer
  - 7.1.1.1 Overview
  - 7.1.1.2 Cancer: North America Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.2 Diabetes
  - 7.1.2.1 Overview
  - 7.1.2.2 Diabetes: North America Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.3 Autoimmune Disease
  - 7.1.3.1 Overview
  - 7.1.3.2 Autoimmune Disease: North America Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.4 Infectious diseases
  - 7.1.4.1 Overview
  - 7.1.4.2 Infectious diseases: North America Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.5 Others
  - 7.1.5.1 Overview
  - 7.1.5.2 Others: North America Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

8. North America Autoinjectors Market Revenue Analysis - by Distribution Channel

8.1 North America Autoinjectors Market Forecast and Analysis by Distribution Channel
- 8.1.1 Hospital Pharmacy
  - 8.1.1.1 Overview
  - 8.1.1.2 Hospital Pharmacy: North America Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 8.1.2 Retail Pharmacy
  - 8.1.2.1 Overview
  - 8.1.2.2 Retail Pharmacy: North America Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 8.1.3 Online Channel
  - 8.1.3.1 Overview
  - 8.1.3.2 Online Channel: North America Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

9. North America Autoinjectors Market - Country Analysis

9.1 North America
- 9.1.1 North America Autoinjectors Market Forecast and Analysis - by Country
  - 9.1.1.1 United States Market
    - 9.1.1.1.1 United States: North America Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 9.1.1.1.2 United States: North America Autoinjectors Market - By Segmentation
      - 9.1.1.1.2.1 Type
      - 9.1.1.1.2.2 Applications
      - 9.1.1.1.2.3 Distribution Channel
  - 9.1.1.2 Canada Market
    - 9.1.1.2.1 Canada: North America Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 9.1.1.2.2 Canada: North America Autoinjectors Market - By Segmentation
      - 9.1.1.2.2.1 Type
      - 9.1.1.2.2.2 Applications
      - 9.1.1.2.2.3 Distribution Channel
  - 9.1.1.3 Mexico Market
    - 9.1.1.3.1 Mexico: North America Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 9.1.1.3.2 Mexico: North America Autoinjectors Market - By Segmentation
      - 9.1.1.3.2.1 Type
      - 9.1.1.3.2.2 Applications
      - 9.1.1.3.2.3 Distribution Channel

10 Autoinjectors Market Industry Landscape

11 - Key Company Profiles

11.1 Phillips-Medisize
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Gerresheimer AG
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 West Pharmaceutical Services Inc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Ypsomed Holding AG
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Stevanato Group SpA
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Becton Dickinson and Co
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Owen Mumford Ltd
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Haselmeier GmbH
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Nemera
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 SHL Medical
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments

12. Appendix

12.1 Glossary
12.2 Research Methodology and Approach
- 12.2.1 Secondary Research
- 12.2.2 Primary Research
- 12.2.3 Market Estimation Approach
  - 12.2.3.1 Supply Side Analysis
  - 12.2.3.2 Demand Side Analysis
- 12.2.4 Research Assumptions and Limitations
- 12.2.5 Currency Conversion
12.3 About The Insight Partners
12.4 Market Intelligence Cloud